View Financial HealthHalberd 배당 및 자사주 매입배당 기준 점검 0/6Halberd 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Oct 27Halberd Corporation Successfully Demonstrates Its Proprietary Breakthrough AI Technology for Behavioral Analysis PlatformHalberd Corporation announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence. In a live demonstration before clinical advisors and company leadership, the NeuroSense AI development team successfully showcased the platform's capacity to: Capture and process real-time behavioral data with professional-grade accuracy; Extract multiple behavioral features simultaneously (vocal patterns, energy levels, temporal characteristics); Generate automated behavioral assessments and visualizations; Demonstrate integration readiness with Claude AI for advanced pattern interpretation and capacity to demonstrate deviations from pre-establish norms. Technology Validation Milestone: The successful demonstration represents a critical development milestone, confirming that: Core Technologies Are Proven: The platform leverages commercially available, enterprise-grade technologies including Claude AI (Anthropic), industry-standard audio processing libraries, and cloud-native architecture patterns. Real-Time Processing Works: The system demonstrated capability to process behavioral data and generate analysis in real-time, a critical requirement for continuous monitoring applications.공시 • May 28Halberd Corporation & Athena Telemedicine Partnership, LLC Announce Clinical Study UpdatesHalberd Corporation in cooperation with Athena Telemedicine Partners, LLC, announced astounding clinical efficacy for patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. previously found that patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. The problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers. Unresponsive to large doses of multiple medications, including Gabapentin, she was placed on LDX and a custom CBD nutraceutical. For the first time in five years, she became almost immediately symptom free. However, LD stopped the LDX based on physician input, and had a recurrence of her symptoms. She was hospitalized for hypertension and stabilized, a significant reduction in medications prescribed ensued, including Gabapentin, and as a result her neuropathy and pruritic symptoms reappeared. She was started on LDX again, but under a titrated dose response protocol that is patent pending, and immediately found relief of both the pain and itching. The company will be offering a 90-day trial for clinicians dealing with dialysis patients on a safety and proof of efficacy FDA study for LDX. platform involves a very low dose initiation and progressive introduction of LDN and methocarbamol with natural cinnamon as a filler to a traditional therapeutic dose. Athena GTX will be supplying wearable WatchDawg™? monitoring and cloud-based acquisition of data through partners at Verizon, to supply objective data on the relief of symptoms to both the participants and physicians/care teams. The company expects a full data presentation for a large and heretofore patient problem that was very difficult to manage. This will be one of two studies with which the company are engaged, with a subsequent well-funded study on PTSD, alcohol use disorder, and suicidal ideation, with an end goal to reduce suicide to be announced shortly. To get the latest on the exciting developments by the Halberd/Athena teams, subscribe by submitting this form. The partnership involves the use of pharmaceuticals, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation.공시 • Dec 03Halberd Corporation Update on Watchdawg®? Ptsd TreatmentHalberd Corporation previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.공시 • Oct 01Halberd & Athena GTX Report Initial Success of WatchDawg®? PTSD Treatment Pilot StudyHalberd Corporation released the results of the recently completed WatchDawg®? Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wear a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participants data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health. During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.공시 • Jul 24Halberd Corporation's Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test ResultsHalberd Corporation announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.공시 • May 03Halberd Announces Patented LDN+ Drug Has Begun Pre-Pilot Trials with Military VeteransHalberd Corporation announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks. The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation. Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.공시 • Apr 05Halberd Corporation's Patented Drug, LDN+ Drug Enters Significant Safety Trial Protocol Under a CRADA Contract for Military Active Duty and VeteransHalberd Corporation's Patented LDN+ Drug has an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just executed Cooperative Research and Development Agreement (CRADA) contract in conjunction with the Exalted Warrior Foundation out of Tampa Florida and three other companies. The six-week safety study subjects will be current active-duty and retired military volunteers for a period of six weeks beginning immediately after execution of Institutional Review Board (IRB) Approval. Halberd's patented LDN+ drug uniquely combines drugs previously approved by the FDA and widely used both individually and in a compounded formulation for many years. In combination, the drugs are believed to act as an antagonist against chemical and alcohol addiction and to relieve pain and anxiety linked to more severe mental health issues facing military today. Pending the results of this limited pilot safety trial, and the results anticipated, higher volumes and more extensive tests of military personnel and veterans will be launched in less than 2 months. The clear pathway forward is to then obtain FDA clearance for the combined new pharmaceutical.공시 • Feb 09Halberd and Mississippi State University to Commence Stage Ii Advanced Tbi Nasal Spray TestingHalberd Corporation's Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed last year with demonstrably compelling results. The advanced program will launch promptly. Numerous federal agencies expressed enthusiasm for the pursuit.공시 • Sep 07Halberd Corporation Announces Astounding Early Test Results of Traumatic Brain Injury Project At Mississippi State UniversityHalberd Corporation's research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of TBI. Neuron Specific Enolase (NSE) is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcomes of TBI. Glial Fibrillary Acid Protein (GFAP) is an indicator of the induction of neuroinflammation and is increased following traumatic brain injury. It is also thought to be an indicator of ongoing neurodegeneration related to numerous other diseases, Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.공시 • Aug 23Halberd Corporation's Successful Completion of Sampling Phase Marks Major Milestone for Project At Mississippi State UniversityHalberd Corporation announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF). Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc. Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.공시 • Feb 14Halberd Corporation Announces Breakthrough in Candida Auris TreatmentHalberd Corporation announced a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria. Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.공시 • Feb 01Halberd to Conduct Animal Tests of Nasal Spray That Blocks Negative Effects of Head TraumaHalberd Corporation confirmed that animal testing at Mississippi State University will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. RussellCarr, of the College of Veterinary Medicine. Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved. Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.공시 • Jan 25Halberd Corporation Agrees to Animal Testing at Mississippi State UniversityHalberd Corporation has agreed to conduct animal testing at Mississippi State University's (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working with Halberd Corporation on an upcoming research project. The project will be investigating the effectiveness of novel therapeutic measures that are under development for combating the damaging effects of traumatic brain injury.공시 • Nov 18Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast CancerHalberd Corporation announced that researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in their latest series of tests. Halberd had been successful previously in eradicating all five cancer disease antigens (PD-1, PDL-1, IL-6, TNF-Alpha, and CTLA-4) attempted to date in a matter of less than 10 minutes exposure to laser emissive energy using Halberd's patent-pending process in conjunction with antibodies conjoined with proprietary nanoparticles. Halberd plans to demonstrate successful eradication of the remaining BTLA cancer disease antigen in near-term scheduled testing.공시 • Nov 01Halberd Corporation announced delayed annual 10-K filingOn 10/31/2022, Halberd Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Oct 13Halberd Corporation Progresses from Eliminating Top Brain Disease Antigens from CSF to Eradication of Interleukin-6 from Human Blood SerumHalberd Corporation demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies. Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd's earlier successful experiments, which eliminated IL-6 from cerebrospinal fluid (CSF) through exposure to laser irradiation, this recent experiment used an engineered antibody with a strong binding affinity to IL-6 which was chemically bonded to a medical grade microbead filter.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 HALB 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: HALB 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Halberd 배당 수익률 vs 시장HALB의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (HALB)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.4%분석가 예측 (HALB) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 HALB 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 HALB 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 HALB 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: HALB 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/15 07:04종가2026/05/15 00:00수익2022/04/30연간 수익2021/07/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Halberd Corporation는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Oct 27Halberd Corporation Successfully Demonstrates Its Proprietary Breakthrough AI Technology for Behavioral Analysis PlatformHalberd Corporation announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence. In a live demonstration before clinical advisors and company leadership, the NeuroSense AI development team successfully showcased the platform's capacity to: Capture and process real-time behavioral data with professional-grade accuracy; Extract multiple behavioral features simultaneously (vocal patterns, energy levels, temporal characteristics); Generate automated behavioral assessments and visualizations; Demonstrate integration readiness with Claude AI for advanced pattern interpretation and capacity to demonstrate deviations from pre-establish norms. Technology Validation Milestone: The successful demonstration represents a critical development milestone, confirming that: Core Technologies Are Proven: The platform leverages commercially available, enterprise-grade technologies including Claude AI (Anthropic), industry-standard audio processing libraries, and cloud-native architecture patterns. Real-Time Processing Works: The system demonstrated capability to process behavioral data and generate analysis in real-time, a critical requirement for continuous monitoring applications.
공시 • May 28Halberd Corporation & Athena Telemedicine Partnership, LLC Announce Clinical Study UpdatesHalberd Corporation in cooperation with Athena Telemedicine Partners, LLC, announced astounding clinical efficacy for patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. previously found that patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. The problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers. Unresponsive to large doses of multiple medications, including Gabapentin, she was placed on LDX and a custom CBD nutraceutical. For the first time in five years, she became almost immediately symptom free. However, LD stopped the LDX based on physician input, and had a recurrence of her symptoms. She was hospitalized for hypertension and stabilized, a significant reduction in medications prescribed ensued, including Gabapentin, and as a result her neuropathy and pruritic symptoms reappeared. She was started on LDX again, but under a titrated dose response protocol that is patent pending, and immediately found relief of both the pain and itching. The company will be offering a 90-day trial for clinicians dealing with dialysis patients on a safety and proof of efficacy FDA study for LDX. platform involves a very low dose initiation and progressive introduction of LDN and methocarbamol with natural cinnamon as a filler to a traditional therapeutic dose. Athena GTX will be supplying wearable WatchDawg™? monitoring and cloud-based acquisition of data through partners at Verizon, to supply objective data on the relief of symptoms to both the participants and physicians/care teams. The company expects a full data presentation for a large and heretofore patient problem that was very difficult to manage. This will be one of two studies with which the company are engaged, with a subsequent well-funded study on PTSD, alcohol use disorder, and suicidal ideation, with an end goal to reduce suicide to be announced shortly. To get the latest on the exciting developments by the Halberd/Athena teams, subscribe by submitting this form. The partnership involves the use of pharmaceuticals, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation.
공시 • Dec 03Halberd Corporation Update on Watchdawg®? Ptsd TreatmentHalberd Corporation previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.
공시 • Oct 01Halberd & Athena GTX Report Initial Success of WatchDawg®? PTSD Treatment Pilot StudyHalberd Corporation released the results of the recently completed WatchDawg®? Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wear a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participants data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health. During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.
공시 • Jul 24Halberd Corporation's Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test ResultsHalberd Corporation announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.
공시 • May 03Halberd Announces Patented LDN+ Drug Has Begun Pre-Pilot Trials with Military VeteransHalberd Corporation announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks. The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation. Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.
공시 • Apr 05Halberd Corporation's Patented Drug, LDN+ Drug Enters Significant Safety Trial Protocol Under a CRADA Contract for Military Active Duty and VeteransHalberd Corporation's Patented LDN+ Drug has an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just executed Cooperative Research and Development Agreement (CRADA) contract in conjunction with the Exalted Warrior Foundation out of Tampa Florida and three other companies. The six-week safety study subjects will be current active-duty and retired military volunteers for a period of six weeks beginning immediately after execution of Institutional Review Board (IRB) Approval. Halberd's patented LDN+ drug uniquely combines drugs previously approved by the FDA and widely used both individually and in a compounded formulation for many years. In combination, the drugs are believed to act as an antagonist against chemical and alcohol addiction and to relieve pain and anxiety linked to more severe mental health issues facing military today. Pending the results of this limited pilot safety trial, and the results anticipated, higher volumes and more extensive tests of military personnel and veterans will be launched in less than 2 months. The clear pathway forward is to then obtain FDA clearance for the combined new pharmaceutical.
공시 • Feb 09Halberd and Mississippi State University to Commence Stage Ii Advanced Tbi Nasal Spray TestingHalberd Corporation's Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed last year with demonstrably compelling results. The advanced program will launch promptly. Numerous federal agencies expressed enthusiasm for the pursuit.
공시 • Sep 07Halberd Corporation Announces Astounding Early Test Results of Traumatic Brain Injury Project At Mississippi State UniversityHalberd Corporation's research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of TBI. Neuron Specific Enolase (NSE) is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcomes of TBI. Glial Fibrillary Acid Protein (GFAP) is an indicator of the induction of neuroinflammation and is increased following traumatic brain injury. It is also thought to be an indicator of ongoing neurodegeneration related to numerous other diseases, Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.
공시 • Aug 23Halberd Corporation's Successful Completion of Sampling Phase Marks Major Milestone for Project At Mississippi State UniversityHalberd Corporation announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF). Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc. Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.
공시 • Feb 14Halberd Corporation Announces Breakthrough in Candida Auris TreatmentHalberd Corporation announced a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria. Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.
공시 • Feb 01Halberd to Conduct Animal Tests of Nasal Spray That Blocks Negative Effects of Head TraumaHalberd Corporation confirmed that animal testing at Mississippi State University will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. RussellCarr, of the College of Veterinary Medicine. Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved. Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.
공시 • Jan 25Halberd Corporation Agrees to Animal Testing at Mississippi State UniversityHalberd Corporation has agreed to conduct animal testing at Mississippi State University's (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working with Halberd Corporation on an upcoming research project. The project will be investigating the effectiveness of novel therapeutic measures that are under development for combating the damaging effects of traumatic brain injury.
공시 • Nov 18Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast CancerHalberd Corporation announced that researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in their latest series of tests. Halberd had been successful previously in eradicating all five cancer disease antigens (PD-1, PDL-1, IL-6, TNF-Alpha, and CTLA-4) attempted to date in a matter of less than 10 minutes exposure to laser emissive energy using Halberd's patent-pending process in conjunction with antibodies conjoined with proprietary nanoparticles. Halberd plans to demonstrate successful eradication of the remaining BTLA cancer disease antigen in near-term scheduled testing.
공시 • Nov 01Halberd Corporation announced delayed annual 10-K filingOn 10/31/2022, Halberd Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Oct 13Halberd Corporation Progresses from Eliminating Top Brain Disease Antigens from CSF to Eradication of Interleukin-6 from Human Blood SerumHalberd Corporation demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies. Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd's earlier successful experiments, which eliminated IL-6 from cerebrospinal fluid (CSF) through exposure to laser irradiation, this recent experiment used an engineered antibody with a strong binding affinity to IL-6 which was chemically bonded to a medical grade microbead filter.